# Juniper Biosciences

Source: https://onco.cc/companies/juniper-biosciences/  
OnCo record `juniper-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Juniper Biosciences develops radioactive scan agents and treatments for cancer. Its most advanced product is a PET tracer that shows low-oxygen areas in HPV-positive head and neck cancers, which could help doctors tailor radiotherapy.

## Summary

Juniper Biosciences LLC is a New Jersey radiopharmaceutical company developing diagnostic and therapeutic agents for oncology. It announced an oversubscribed, upsized USD 40 million seed financing on 1 December 2025 through its parent Juniper Radiopharma LLC, co-led by NovaCapital, high-net-worth individuals and members of the Club degli Investitori; Alex Agnoletto is CEO. Its pipeline lists JBS-003 (F-MISO, fluorine-18 fluoromisonidazole) for imaging hypoxic tumour cells in HPV-positive head and neck cancer, which the company says has FDA Breakthrough Therapy Designation; JBS-002, a gallium-68 PSMA agent; JBS-004, a fluorine-18 tracer for Alzheimer's disease; and JBS-005, undisclosed alpha, beta and gamma emitter programmes.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Juniper Radiopharma
- HQ: Bedminster, NJ
- Type: radiopharma
- Website: https://juniperbiosci.com/

## Notes

- Founding year not stated. The seed release gives Bridgewater, NJ; the website now gives a Bedminster, NJ address. The Breakthrough Therapy Designation for JBS-003 is stated on the company website and was not checked against an FDA source. Stages of the pipeline programmes could not be read from the website.

## Sources

- Official website: https://juniperbiosci.com/
- Seed financing release (republished by Santelog): https://www.santelog.com/actualites-sante-nasdaq/juniper-biosciences-raises-oversubscribed-and-upsized-40-million-seed

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [HPV-positive oropharyngeal cancer](https://onco.cc/cancers/hpv-positive-oropharyngeal-cancer/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [PET (positron emission tomography)](https://onco.cc/technologies/pet/), [PSMA PET](https://onco.cc/technologies/psma-pet/), [Tumour hypoxia: imaging and modification](https://onco.cc/technologies/tumour-hypoxia-modification/)
- targets: [PSMA](https://onco.cc/targets/psma/)

---
JSON: https://onco.cc/api/v1/entities/juniper-biosciences.json